Brief: Sensorion FY Net Loss Narrows To EUR 9 Million

Sensorion SA

18/03/2021 06:55

March 18 (Reuters) - SENSORION SA  ALSEN.PA :
    * CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 62.2 MILLION AT
31
DECEMBER 2020 COMPARED TO EUR 30.4 MILLION AT DECEMBER 31, 2019
    * ENROLMENT OF SENS-401 PHASE 2 SSNHL CLINICAL STUDY
PROGRESSING
    * EXPANDING INTERNAL GENE THERAPY CAPABILITIES INCLUDING
AAV,
ANALYTICAL AND PROCESS DEVELOPMENT
    * REPORTED POSITIVE PRELIMINARY NON-HUMAN PRIMATE DATA FOR
THE
OTOF PROGRAM
    * FY OPERATING REVENUE EUR 2.4 MILLION VERSUS EUR 2.5
MILLION YEAR
AGO
    * NET LOSS WAS -EUR 9.0 MILLION AT 31 DECEMBER 2020 COMPARED
WITH
-EUR 12.1 MILLION AT 31 DECEMBER 2019
    * IN FEBRUARY 2021, EXTENDED GENE THERAPY PORTFOLIO BY
ADDING A
THIRD PROGRAM FOCUSED ON THE  GJB2 MUTATIONS
    * THERE IS A RISK OF ANOTHER GUIDANCE CHANGE ON AVAILABILITY
OF
PHASE 2 RESULTS WITH SENS-401 IN SSNHL
    * SUCH AN EVENTUALITY COULD, HOWEVER, HAVE A SIGNIFICANT
ADVERSE
IMPACT ON COMPANY'S BUSINESS, RESULTS, AND FINANCIAL POSITION
    * COMPANY BELIEVES IT WILL BE ABLE TO FUND ITS OPERATIONS
UNTIL
END OF SECOND HALF OF 2022

Source text for Eikon:  ID:nBw22Z2xma 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))